@article {Winner:November/December 2006:0017-8748:1503,
	author = "Winner, Paul",
	author = "Gendolla, Astrid",
	author = "Stayer, Catherine",
	author = "Wang, Steven",
	author = "Yuen, Eric",
	author = "Battisti, Wendy P.",
	author = "Nye, Jeffrey S.",
	title = "Topiramate for Migraine Prevention in Adolescents: A Pooled Analysis of Efficacy and Safety",
	journal = "Headache: The Journal of Head and Face Pain",
	volume = "46",
	year = "November/December 2006",
	abstract = "Objective.&#8212;To characterize the efficacy and safety of topiramate for migraine prevention in adolescents from 3 randomized, 26-week, double-blind, placebo-controlled trials.<P></P>Background.&#8212;Limited information is available regarding the efficacy and safety of prophylactic medications for treatment of adolescent migraine, a significant health problem. In studies that included adults and children, topiramate 100 and 200 mg&#47;day were effective and generally well-tolerated in the prevention of migraine headache.<P></P>Methods.&#8212;We performed a post hoc subset analysis of the efficacy and safety data from the 51 patients, ages 12-17 years, enrolled in 3 pivotal trials of topiramate for migraine prophylaxis.<P></P>Results.&#8212;Daily treatment with topiramate 50, 100, and 200 mg for 26 weeks reduced monthly migraine frequency from baseline 46&#37; (<I>P</I>&#61; .07), 63&#37; (<I>P</I>&#61; .02), and 65&#37; (<I>P</I>&#61; .04), respectively, compared with placebo (16&#37;). Similarly, topiramate reduced both the monthly mean number of migraine days (1, 4, and 5 days for topiramate 50, 100, and 200 mg&#47;day, respectively, vs 1 day for placebo) and percentage of days during which acute migraine medications were administered (59&#37;, 54&#37;, and 67&#37; for topiramate 50, 100, and 200 mg&#47;day, respectively, vs 42&#37; for placebo), although the treatment differences did not reach nominal statistical significance. Topiramate 200 mg&#47;day did not appear to offer greater efficacy than 100 mg&#47;day. Treatment was generally well-tolerated, although adverse events were most frequent in the 200 mg&#47;day dose group. <P></P>Conclusions.&#8212;This post hoc subset analysis suggests that topiramate 100 and 200 mg&#47;day, and possibly 50 mg&#47;day, administered prophylactically for 26 weeks may reduce migraine in adolescents.<P></P>(<I>Headache</I> 2006;46:1503-1510)",
	pages = "1503-1510(8)",
	url = "http://www.ingentaconnect.com/content/bsc/hed/2006/00000046/00000010/art00006"
	doi = "doi:10.1111/j.1526-4610.2006.00610.x"
}